세계의 액체생검 시장 : 암별, 사용법별, 마커별, 장소별, 제품별, 가격 및 수량 전망 - 경영진 컨설턴트 가이드 (2025-2029년) - 인공지능(AI)의 영향

Liquid Biopsy Markets By Cancer, Usage, Biomarker, Place, & Product With Price And Volume Outlook. Including Executive and Consultant Guides and Impact of Artificial Intelligence 2025-2029

US $ 6,995 ￦ 9,742,000

PDF (Single User License)

PDF 보고서를 1명(One device)만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,495 ￦ 14,617,000

PDF (Five User License)

PDF 보고서를 동일 사업장의 5명(Five devices)까지 이용할 수 있는 라이선스입니다. 인쇄 불가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 13,995 ￦ 19,492,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄는 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

이 보고서는 스크리닝, 진단, 치료 선택, 최소잔존병변, 스크리닝 시장 잠재력을 탐구합니다. 암 유형별 가격 및 수량 전망을 제공합니다. 또한 순환 종양세포, 세포 유리 DNA, 엑소좀 등의 전문용어를 알기 쉽게 설명합니다.

체외 혈액 검사로 암 DNA를 확인하는 것은 암 진단에 혁명을 일으키고 있습니다. 이 기술로 인해 암 검진 검사가 대중화될 가능성이 생겼습니다.

기술의 발전은 시장보다 빠릅니다. 혈액 샘플을 통해 질병을 결정적으로 파악하는 새로운 기술은 값비싼 침습적 외과적 생검을 대체할 준비가 되어 있습니다. 이 보고서는 5년 후 시장 규모를 예측했습니다. 또한, 국가별, 암종별, 스크리닝, 진단, 치료법 선택, 재발 모니터링 등 4가지 용도별로 잠재적인 시장 규모를 조사했습니다.

이 보고서에는 폐암, 유방암, 대장암, 전립선암, 자궁경부암, 기타 암, 검진/조기발견, 진단, 치료 모니터링, 재발 모니터링 등 15개 국가와 4개 지역에 대한 세부적인 분석이 수록되어 있습니다.

최신 데이터를 통해 자신 있게 투자 판단과 평가를 내릴 수 있습니다.

세계의 액체생검(Liquid Biopsy) 시장에 대해 조사했으며, 시장 개요와 함께 암별/용도별/마커별/지역별/제품별 동향, 시장 진출 기업 프로파일 등을 정리하여 전해드립니다.

목차

제1장 시장 가이드

제2장 서론과 시장의 정의

• 액체생검이란 무엇인가?
• 시퀀싱 혁명
• 시장 정의
• 조사 방법
• 시점 : 헬스케어와 IVD 업계

제3장 시장 개요

• 시장 참여 조직
  • 학술연구기관
  • 진단 시험 개발자
  • 계측 기기 공급업체
  • 약품 및 시약 제조업체
  • 병리 공급업체
  • 독립계 임상 실험실
  • 공공 국립 및 지역 연구소
  • 병원 검사실
  • 임상 실험실
  • 감사기관
  • 인증기관
• 생검 사용
• 생검 부위
• 현황 - 생검 분석
• 암 증거 - 액체생검 기술
• 암치료 프로토콜이 위기에 직면
• 산업 구조의 영향

제4장 시장 동향

• 성장 촉진요인
• 성장 억제요인
• 계측과 자동화
• 진단 기술 개발

제5장 액체생검의 최근 동향

제6장 주요 기업 개요

• Admera Health, LLC
• Abbott Laboratories
• AccuraGen Inc.
• Acuamark Diagnostics
• Agilent
• Amoy Diagnostics Co., Ltd.
• Anchor Dx
• ANGLE plc
• Applied DNA Sciences
• ARUP Laboratories
• AVIVA Systems Biology
• Baylor Miraca Genetics Laboratories
• Beckman Coulter Diagnostics(Danaher)
• Becton, Dickinson and Company
• Berkley Lights
• BGI Genomics Co. Ltd
• BillionToOne
• Bioarray Genetics
• Biocartis
• Biocept, Inc.
• Biodesix Inc.
• BioFluidica
• Biolidics Ltd
• bioMerieux Diagnostics
• Bioneer Corporation
• Bio-Rad Laboratories, Inc
• Bio-Techne
• Bioview
• Burning Rock
• Cardiff Oncology
• CareDx
• Caris Molecular Diagnostics
• CellCarta
• CellMax Life
• Cepheid(Danaher)
• Circulogene
• Cizzle Biotech
• Clearbridge Biomedics
• Clinical Genomics
• Cytolumina Technologies Corp.
• Datar Cancer Genetics Limited
• Diagnologix LLC
• Dxcover
• Element Biosciences
• Enzo Biochem
• Epic Sciences
• Epigenomics AG
• Eurofins Scientific
• Exact Sciences
• Fluxion Biosciences(Cell Microsystems)
• Freenome
• Fyr Diagnostics
• GeneFirst Ltd.
• Genetron Holdings
• GILUPI Nanomedizin
• Guardant Health
• HansaBiomed
• Haystack Oncology(Quest Dx)
• iCellate
• ICON PLC
• Illumina
• Incell Dx
• Inivata
• INOVIQ
• Invitae Corporation
• J&J Innovative Medicine
• Lucence Health
• Lunglife AI Inc
• MDNA Life SCIENCES, Inc.
• MDx Health
• Menarini Silicon Biosystems
• Mesa Laboratories, Inc.
• Millipore Sigma
• Miltenyi Biotec
• miR Scientific
• Myriad Genetics
• Nanostring
• NantHealth, Inc.
• Natera
• NeoGenomics
• Novogene
• On-Chip Biotechnologies
• Oncocyte
• OncoDNA
• Oncimmune
• Oxford Nanopore Technologies
• PamGene
• Panagene
• Personalis
• PGDx(Labcorp)
• PrecisionMed
• Predicine
• Predictive Oncology
• Prenetics
• Promega
• Qiagen
• Rarecells SAS
• RareCyte
• Revvity
• Roche Diagnostics
• Saga Diagnostics
• Screencell
• Siemens Healthineers
• simfo GmbH
• Singlera Genomics Inc.
• Singular Genomics
• Standard BioTools
• Stilla Technologies
• Superfluid Dx
• Sysmex Inostics
• Tempus Labs, Inc.
• Thermo Fisher Scientific
• Todos Medical
• Ultima Genomics
• Veracyte
• VolitionRX
• Vortex Biosciences

제7장 세계의 액체생검 시장

• 국가별 세계 시장 개요
• 암별 세계 시장 - 개요
• 사용법별 세계 시장 - 개요
• 장소별 세계 시장 - 개요
• 바이오마커별 세계 시장 - 개요
• 제품별 세계 시장 - 개요

제8장 세계의 액체생검 시장 - 암별

• 흉부
• 대장
• 경부
• 폐
• 전립선
• 기타

제9장 세계의 액체생검 시장 - 사용법별

• 스크리닝
• 진단
• 치료
• 관찰

제10장 세계의 액체생검 시장 - 지역별

• 병원 검사실
• 실험실 서비스
• 외래 실험실
• 기타

제11장 세계의 액체생검 시장 - 마커별

• 순환종양세포
• 유리 DNA
• 소포
• 기타

제12장 세계의 액체생검 시장 - 제품별

• 키트
• 기기
• 서비스

제13장 부록

LSH

영문 목차

영문목차

OVERVIEW:

The Screening, Diagnostic, Therapy Selection, Minimal Residual Disease and Screening Market Potential are all explored in this report. We look at Price and Volume Outlooks by type of cancer. This report provides detailed analysis.

Circulating Tumor Cells? Cell Free DNA? Exosomes? Find out about the technology in readily understood terms that explain the jargon. Find the opportunities and the pitfalls. Understand growth expectations and the ultimate potential market size.

A revolution in cancer diagnostics is occurring using in vitro blood testing to identify cancer DNA. The technology has created the possibility of widespread cancer screening tests.

The technology is moving faster than the market. New technology that definitively identifies disease conditions from blood samples is poised to replace expensive invasive surgical biopsy procedures. What Growth Phase is the market in? The impact on the health care industry is enormous. The report forecasts the market size looking out 5 years. In addition, the report looks at potential market sizes by country, by cancer and by the four types of usage: screening, diagnosis, therapy selection and recurrence monitoring.

The report includes detailed breakouts for 15 Countries and 4 Regions along with breakouts for Lung, Breast, Colorectal, Prostate, Cervical, and Other Cancers as well as breakouts by Screening/Early Detection, Diagnostic, Therapy Monitoring and Recurrence Monitoring.

All report data is available in Excel format on request.

Make investment decisions and valuations with confidence using the latest data.

Table of Contents

1. Market Guides

• 1.1. Liquid Biopsy Market - Strategic Situation Analysis
• 1.2. Guide for Executives, Marketing, Sales, and Business Development Staff
• 1.3. Guide for Management Consultants and Investment Advisors
• 1.4. Impact of Artificial Intelligence on Liquid Biopsy Market

2. Introduction and Market Definition

• 2.1. What is Liquid Biopsy?
• 2.2. The Sequencing Revolution
• 2.3. Market Definition
  • 2.3.1. Revenue Market Size
• 2.4. Methodology
  • 2.4.1. Methodology
  • 2.4.2. Sources
  • 2.4.3. Authors
• 2.5. Perspective: Healthcare and the IVD Industry
  • 2.5.1. Global Healthcare Spending
  • 2.5.2. Spending on Diagnostics
  • 2.5.3. Important Role of Insurance for Diagnostics

3. Market Overview

• 3.1. Players in a Dynamic Market
  • 3.1.1. Academic Research Lab
  • 3.1.2. Diagnostic Test Developer
  • 3.1.3. Instrumentation Supplier
  • 3.1.4. Chemical/Reagent Supplier
  • 3.1.5. Pathology Supplier
  • 3.1.6. Independent Clinical Laboratory
  • 3.1.7. Public National/regional Laboratory
  • 3.1.8. Hospital Laboratory
  • 3.1.9. Physicians Office Lab (POLS)
  • 3.1.10. Audit Body
  • 3.1.11. Certification Body
• 3.2. Using Biopsies
  • 3.2.1. Cancer
  • 3.2.2. Precancerous conditions
  • 3.2.3. Inflammatory conditions
• 3.3. Biopsy Sites
• 3.4. The Situation Today - Biopsy Analysis
• 3.5. Evidence of Cancer - Liquid Biopsy Technology
  • 3.5.1. The Big Picture on Liquid Biopsy Technology
  • 3.5.2. The Role of CTCs
  • 3.5.3. Application of CTCs
  • 3.5.4. CellSearch Detection- Ultimate Sensitivity
  • 3.5.5. Epic Sciences Detection- Imaging Takes the Lead
  • 3.5.6. Maintrac Detection - The Microscope
  • 3.5.7. Other Methods
  • 3.5.8. ctDNA Role
  • 3.5.9. ctDNA Applications
  • 3.5.10. Exosomes and Micro Vesicles - New Kid on the Block
  • 3.5.11. The Multiple Play
• 3.6. Cancer Treatment Protocol Under Siege
  • 3.6.1. Issues to Liquid Biopsy Adoption - Double Diagnostics
  • 3.6.2. The Cancer Screening Market Opportunity
    • 3.6.2.1. GRAIL - What Is It?
  • 3.6.3. Cancer Management vs. Diagnosis
    • 3.6.3.1. The Role of Risk Assessment
    • 3.6.3.2. Managing Therapy
    • 3.6.3.3. Monitoring Disease - What Is It?
  • 3.6.4. Phases of Adoption - Looking into The Future
  • 3.6.5. The Promise of Liquid Biopsy
• 3.7. Structure of Industry Plays a Part
  • 3.7.1. Hospital Testing Share
  • 3.7.2. Economies of Scale
    • 3.7.2.1. Hospital vs. Central Lab
  • 3.7.3. Physician Office Lab's
  • 3.7.4. Physician's and POCT

4. Market Trends

• 4.1. Factors Driving Growth
  • 4.1.1. Non-Invasive Game Changer
  • 4.1.2. Lower Cost
  • 4.1.3. Greater Accuracy
  • 4.1.4. Wide Range of Potential Uses
  • 4.1.5. Aging Population
• 4.2. Factors Limiting Growth
  • 4.2.1. Lower prices
  • 4.2.2. Lack of Standards
  • 4.2.3. Protocol Resistance
  • 4.2.4. Initial Adoption Cost
  • 4.2.5. Conclusion
• 4.3. Instrumentation and Automation
  • 4.3.1. Instruments Key to Market Share
  • 4.3.2. Bioinformatics Plays a Role
• 4.4. Diagnostic Technology Development
  • 4.4.1. Next Generation Sequencing Fuels a Revolution
  • 4.4.2. Impact of NGS on pricing
  • 4.4.3. Pharmacogenomics Blurs Diagnosis and Treatment
  • 4.4.4. CGES Testing, A Brave New World
  • 4.4.5. Biochips/Giant magneto resistance based assay

5. Liquid Biopsy Recent Developments

• 5.1. Recent Developments - Importance and How to Use This Section
  • 5.1.1. Importance of These Developments
  • 5.1.2. How to Use This Section
• 5.2. Liquid Biopsy Firm QCDx Closes Financing
• 5.3. LabCorp Launches Liquid Biopsy
• 5.4. OncoHelix, AstraZeneca to Provide Prostate Cancer Liquid Biopsy Testing
• 5.5. Liquid Biopsy Developer Oxford Cancer Analytics Raises $11M
• 5.6. GeneCentric Therapeutics Launches ExpressCT Liquid Biopsy Platform
• 5.7. Syantra Closes Financing
• 5.8. Concerns Over Grail Test Effectiveness
• 5.9. Guardant Health Sues Tempus for Patent Infringement
• 5.10. Delfi Dx Liquid Biopsy Technology Shows Promise
• 5.11. Thermo Fisher Scientific, Bayer to Develop NGS-Based CDx
• 5.12. Grail Details TBE Method for Cancer Monitoring
• 5.13. Naveris HPV Liquid Biopsy Test Gets Medicare Coverage
• 5.14. Personalis NeXT Personal Dx Early-Access Program
• 5.15. Liquid Biopsy Shortens Time to Treatment
• 5.16. Guardant Health MRD Test Garners Coverage
• 5.17. IMBdx, AstraZeneca Expand Prostate Cancer Liquid Biopsy Partnership
• 5.18. FoundationOne Liquid Biopsy Assay Gets FDA OK as Companion Diagnostic
• 5.19. Epic Sciences Raises $24M for Breast Cancer Liquid Biopsy Test
• 5.20. GenoMe Diagnostics Preparing DPCR-Based Ovarian Cancer Test
• 5.21. Sophia Genetics to Commercialize Liquid Biopsy Test
• 5.22. Agilent, Qiagen Nab FDA Approvals for Lung Cancer Treatment CDx
• 5.23. Liquid Biopsy Startup Haystack Oncology Raises $56M
• 5.24. Hedera Dx to Launch Liquid Biopsy Streamlined Platform
• 5.25. PamGene Expanding Liquid Biopsy Assays
• 5.26. Liquid Biopsy Firm Hedera Dx Raises Euro-14M
• 5.27. MDxHealth Plans One-Stop Shop for Prostate Cancer Dx
• 5.28. Precision Oncology Dx Access Varies Widely in Europe
• 5.29. Extracellular Vesicles Show Promise as Early-Stage Cancer Diagnostic
• 5.30. Predicine Receives CE Mark for Blood and Urine Liquid Biopsy
• 5.31. BillionToOne Launches First Liquid Biopsy Products
• 5.32. Dxcover Advances Multicancer Detection Platform
• 5.33. CorePath Laboratories, Cizzle Biotechnology Partner on Lung Cancer Blood Test
• 5.34. Illumina Sues Guardant Health Over Patents
• 5.35. Invitae to Expand Cancer Testing Portfolio
• 5.36. Cancer Centre, Inivata Partner on Clinical Liquid Biopsy Studies
• 5.37. IVBH Bio Takes Aim at With Liquid Biopsy Incubator
• 5.38. Molecular Health, Eone-Diagnomics Ink Liquid Biopsy Partnership
• 5.39. Delfi Diagnostics Looks To Fragmentation-Based Liquid Biopsy Tech
• 5.40. BillionToOne Adapting Fetal Dx Tech for Liquid Biopsy
• 5.41. EDGC to Expand Liquid Biopsy Space With Cell-Free DNA Platform
• 5.42. Liquid Biopsy Startup BioCaptiva Raises Pound-1M in Seed Funding
• 5.43. Agilent Enters Liquid Biopsy Market with Resolution Biosciences Acquisition
• 5.44. Bio-Techne to Acquire Asuragen for up to $320M
• 5.45. Personalis Broadens Liquid Biopsy Offering
• 5.46. Exact Sciences to Offer End-to-End Cancer Testing With Ashion Acquisition
• 5.47. Delfi Diagnostics Plans Multi-Cancer Screening Test
• 5.48. Menarini's CellSearch Shows Potential to Predict Breast Cancer Prognosis, Treatment Response
• 5.49. Liquid Biopsy NGS Panels - Diverse Test Claims
• 5.50. CMS Colon Cancer Screening Memo Bodes Well for Assays
• 5.51. Natera Liquid Biopsy Test Coverage to Expand
• 5.52. Freenome Closes Financing to Support Early Cancer Detection Trial
• 5.53. C$2.6M Liquid Biopsy Initiative
• 5.54. NeoGenomics, Inivata Partner for Lung Cancer Liquid Biopsy
• 5.55. Liquid Biopsy Shows Promise as Screen for Cancers
• 5.56. Inivata launches RaDaR(TM) for the detection of residual disease and recurrence
• 5.57. Liquid Biopsy Assay Detects 50+ Types of Cancer
• 5.58. Liquid Biopsy Study Confirms Concordance with Tissue Biopsy

6. Profiles of Key Players

• 6.1. Admera Health, LLC
• 6.2. Abbott Laboratories
• 6.3. AccuraGen Inc.
• 6.4. Acuamark Diagnostics
• 6.5. Agilent
• 6.6. Amoy Diagnostics Co., Ltd.
• 6.7. Anchor Dx
• 6.8. ANGLE plc
• 6.9. Applied DNA Sciences
• 6.10. ARUP Laboratories
• 6.11. AVIVA Systems Biology
• 6.12. Baylor Miraca Genetics Laboratories
• 6.13. Beckman Coulter Diagnostics (Danaher)
• 6.14. Becton, Dickinson and Company
• 6.15. Berkley Lights
• 6.16. BGI Genomics Co. Ltd
• 6.17. BillionToOne
• 6.18. Bioarray Genetics
• 6.19. Biocartis
• 6.20. Biocept, Inc.
• 6.21. Biodesix Inc.
• 6.22. BioFluidica
• 6.23. Biolidics Ltd
• 6.24. bioMerieux Diagnostics
• 6.25. Bioneer Corporation
• 6.26. Bio-Rad Laboratories, Inc
• 6.27. Bio-Techne
• 6.28. Bioview
• 6.29. Burning Rock
• 6.30. Cardiff Oncology
• 6.31. CareDx
• 6.32. Caris Molecular Diagnostics
• 6.33. CellCarta
• 6.34. CellMax Life
• 6.35. Cepheid (Danaher)
• 6.36. Circulogene
• 6.37. Cizzle Biotech
• 6.38. Clearbridge Biomedics
• 6.39. Clinical Genomics
• 6.40. Cytolumina Technologies Corp.
• 6.41. Datar Cancer Genetics Limited
• 6.42. Diagnologix LLC
• 6.43. Dxcover
• 6.44. Element Biosciences
• 6.45. Enzo Biochem
• 6.46. Epic Sciences
• 6.47. Epigenomics AG
• 6.48. Eurofins Scientific
• 6.49. Exact Sciences
• 6.50. Fluxion Biosciences (Cell Microsystems)
• 6.51. Freenome
• 6.52. Fyr Diagnostics
• 6.53. GeneFirst Ltd.
• 6.54. Genetron Holdings
• 6.55. GILUPI Nanomedizin
• 6.56. Guardant Health
• 6.57. HansaBiomed
• 6.58. Haystack Oncology (Quest Dx)
• 6.59. iCellate
• 6.60. ICON PLC
• 6.61. Illumina
• 6.62. Incell Dx
• 6.63. Inivata
• 6.64. INOVIQ
• 6.65. Invitae Corporation
• 6.66. J&J Innovative Medicine
• 6.67. Lucence Health
• 6.68. Lunglife AI Inc
• 6.69. MDNA Life SCIENCES, Inc.
• 6.70. MDx Health
• 6.71. Menarini Silicon Biosystems
• 6.72. Mesa Laboratories, Inc.
• 6.73. Millipore Sigma
• 6.74. Miltenyi Biotec
• 6.75. miR Scientific
• 6.76. Myriad Genetics
• 6.77. Nanostring
• 6.78. NantHealth, Inc.
• 6.79. Natera
• 6.80. NeoGenomics
• 6.81. Novogene
• 6.82. On-Chip Biotechnologies
• 6.83. Oncocyte
• 6.84. OncoDNA
• 6.85. Oncimmune
• 6.86. Oxford Nanopore Technologies
• 6.87. PamGene
• 6.88. Panagene
• 6.89. Personalis
• 6.90. PGDx (Labcorp)
• 6.91. PrecisionMed
• 6.92. Predicine
• 6.93. Predictive Oncology
• 6.94. Prenetics
• 6.95. Promega
• 6.96. Qiagen
• 6.97. Rarecells SAS
• 6.98. RareCyte
• 6.99. Revvity
• 6.100. Roche Diagnostics
• 6.101. Saga Diagnostics
• 6.102. Screencell
• 6.103. Siemens Healthineers
• 6.104. simfo GmbH
• 6.105. Singlera Genomics Inc.
• 6.106. Singular Genomics
• 6.107. Standard BioTools
• 6.108. Stilla Technologies
• 6.109. Superfluid Dx
• 6.110. Sysmex Inostics
• 6.111. Tempus Labs, Inc.
• 6.112. Thermo Fisher Scientific
• 6.113. Todos Medical
• 6.114. Ultima Genomics
• 6.115. Veracyte
• 6.116. VolitionRX
• 6.117. Vortex Biosciences

7. The Global Market for Liquid Biopsy Diagnostics

• 7.1. Global Market Overview by Country
  • 7.1.1. Table - Global Market by Country
  • 7.1.2. Chart - Global Market by Country
• 7.2. Global Market by Cancer - Overview
  • 7.2.1. Table - Global Market by Cancer
  • 7.2.2. Chart - Global Market by Cancer - Base/Final Year Comparison
  • 7.2.3. Chart - Global Market by Cancer - Base Year
  • 7.2.4. Chart - Global Market by Cancer - End Year
  • 7.2.5. Chart - Global Market by Cancer - Share by Year
  • 7.2.6. Chart - Global Market by Cancer - Segments Growth
• 7.3. Global Market by Usage - Overview
  • 7.3.1. Table - Global Market by Usage
  • 7.3.2. Chart - Global Market by Usage - Base/Final Year Comparison
  • 7.3.3. Chart - Global Market by Usage - Base Year
  • 7.3.4. Chart - Global Market by Usage - End Year
  • 7.3.5. Chart - Global Market by Usage - Share by Year
  • 7.3.6. Chart - Global Market by Usage - Segments Growth
• 7.4. Global Market by Place - Overview
  • 7.4.1. Table - Global Market by Place
  • 7.4.2. Chart - Global Market by Place - Base/Final Year Comparison
  • 7.4.3. Chart - Global Market by Place - Base Year
  • 7.4.4. Chart - Global Market by Place - End Year
  • 7.4.5. Chart - Global Market by Place - Share by Year
  • 7.4.6. Chart - Global Market by Place - Segments Growth
• 7.5. Global Market by Marker - Overview
  • 7.5.1. Table - Global Market by Marker
  • 7.5.2. Chart - Global Market by Marker - Base/Final Year Comparison
  • 7.5.3. Chart - Global Market by Marker - Base Year
  • 7.5.4. Chart - Global Market by Marker - End Year
  • 7.5.5. Chart - Global Market by Marker - Share by Year
  • 7.5.6. Chart - Global Market by Marker - Segments Growth
• 7.6. Global Market by Product - Overview
  • 7.6.1. Table - Global Market by Product
  • 7.6.2. Chart - Global Market by Product - Base/Final Year Comparison
  • 7.6.3. Chart - Global Market by Product - Base Year
  • 7.6.4. Chart - Global Market by Product - End Year
  • 7.6.5. Chart - Global Market by Product - Share by Year
  • 7.6.6. Chart - Global Market by Product - Segments Growth

8. Global Liquid Biopsy Diagnostic Markets - By Cancer

• 8.1. Breast
  • 8.1.1. Table Breast - by Country
  • 8.1.2. Table Breast - by Country, Price
  • 8.1.3. Table Breast - by Country Volume
  • 8.1.4. Chart - Breast Growth
• 8.2. Colorectal
  • 8.2.1. Table Colorectal - by Country
  • 8.2.2. Table Colorectal - by Country, Price
  • 8.2.3. Table Colorectal - by Country, Volume
  • 8.2.4. Chart - Colorectal Growth
• 8.3. Cervical
  • 8.3.1. Table Cervical - by Country
  • 8.3.2. Table Cervical - by Country, Price
  • 8.3.3. Table Cervical - by Country, Volume
  • 8.3.4. Chart - Cervical Growth
• 8.4. Lung
  • 8.4.1. Table Lung - by Country
  • 8.4.2. Table Lung - by Country, Price
  • 8.4.3. Table Lung - by Country, Volume
  • 8.4.4. Chart - Lung Growth
• 8.5. Prostate
  • 8.5.1. Table Prostate - by Country
  • 8.5.2. Table Prostate - by Country, Price
  • 8.5.3. Table Prostate - by Country, Volume
  • 8.5.4. Chart - Prostate Growth
• 8.6. Other
  • 8.6.1. Table Other - by Country
  • 8.6.2. Table Other - by Country, Price
  • 8.6.3. Table Other - by Country, Volume
  • 8.6.4. Chart - Other Growth

9. Global Liquid Biopsy Diagnostic Markets - by Usage

• 9.1. Screening
  • 9.1.1. Table Screening - by Country
• 9.2. Chart - Screening Growth
• 9.3. Diagnostic
  • 9.3.1. Table Diagnostic - by Country
  • 9.3.2. Chart - Diagnostic Growth
• 9.4. Therapy
  • 9.4.1. Table Therapy - by Country
  • 9.4.2. Chart - Therapy Growth
• 9.5. Monitor
  • 9.5.1. Table Monitor - by Country
  • 9.5.2. Chart - Monitor Growth

10. Global Liquid Biopsy Diagnostic Markets - by Place

• 10.1. Hospital Lab
  • 10.1.1. Table Hospital Lab - by Country
  • 10.1.2. Chart - Hospital Lab Growth
• 10.2. Lab Service
  • 10.2.1. Table Lab Service - by Country
  • 10.2.2. Chart - Lab Service Growth
• 10.3. Lab Outpatient
  • 10.3.1. Table Lab Outpatient - by Country
  • 10.3.2. Chart - Lab Outpatient Growth
• 10.4. Other Lab
  • 10.4.1. Table Other Lab - by Country
  • 10.4.2. Chart - Other Lab Growth

11. Global Liquid Biopsy Diagnostic Markets - by Marker

• 11.1. Circulating Tumor Cell
  • 11.1.1. Table Circulating Tumor Cell - by Country
  • 11.1.2. Chart - Circulating Tumor Cell Growth
• 11.2. Cell Free DNA
  • 11.2.1. Table Cell Free DNA - by Country
  • 11.2.2. Chart - Cell Free DNA Growth
• 11.3. Vesicle
  • 11.3.1. Table Vesicle - by Country
  • 11.3.2. Chart - Vesicle Growth
• 11.4. Other Marker
  • 11.4.1. Table Other Marker - by Country
  • 11.4.2. Chart - Other Marker Growth

12. Global Liquid Biopsy Diagnostic Markets - by Product

• 12.1. Kits
  • 12.1.1. Table Kits - by Country
  • 12.1.2. Chart - Kits Growth
• 12.2. Instruments
  • 12.2.1. Table Instruments - by Country
  • 12.2.2. Chart - Instruments Growth
• 12.3. Service
  • 12.3.1. Table Service - by Country
  • 12.3.2. Chart - Service Growth

13. Appendices

• 13.1. Growth of Approved IVD Test Menu
• 13.2. Growth of Approved Average IVD Test Fee
• 13.3. The Most Used IVD Assays
• 13.4. The Highest Grossing Assays
• 13.5. Laboratory Fees Schedule

관련자료